10% Owner ADAR1 Capital Adds $1.6M More Tenax Stock After Phase 3 Miss
TENX sits 54% above its 52-week low of $1.31.
Summary
ADAR1 Capital Management bought 900,000 shares of Tenax for $1.6 million, increasing its stake to 6.5 million shares. This is the second large purchase by the 10% owner since the Phase 3 trial miss.
Key Events · Ownership and Investor Activity · TENX
-
10% Owner Buys $1.6M More Stock
ADAR1 Capital Management purchased 900,000 shares at a weighted average price of $1.7824 on September 3, 2026, for a total of $1,604,160.
-
Stake Increases to 6.5M Shares
Post-transaction holdings total 6,524,151 shares, up from 5,624,151 shares before the purchase.
-
Second Large Buy Since Trial Miss
This follows a $1.81 million purchase disclosed on August 24, 2026, days after the Phase 3 LEVEL trial missed its primary endpoint.
-
Institutional Conviction Signal
The continued accumulation by a 10% owner suggests confidence in the prespecified subgroup and biomarker data highlighted by management after the trial miss.
Analysis · TENX · Life Sciences
ADAR1 Capital Management, a 10% owner, bought another 900,000 shares for $1.6 million on September 3, bringing its total position to 6.5 million shares. This follows a $1.81 million purchase disclosed on August 24, just days after the Phase 3 LEVEL trial missed its primary endpoint. The continued accumulation by a large institutional holder suggests conviction in the subgroup and biomarker data that management highlighted after the trial miss, despite the stock trading near $2. The purchase represents a meaningful increase in ownership and reinforces the insider accumulation signal seen over the past 90 days.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.7% of the 1838 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TENX was trading at $2.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $74.1M. The 52-week trading range was $1.31 to $19.40. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.